Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by JDavenporton Nov 15, 2022 3:33pm
135 Views
Post# 35101066

RE:RE:RE:Grow up and move on please...

RE:RE:RE:Grow up and move on please...I was asked a question about my CVR comments, specifically about how the acquiring companies place a value on their CVR liability for reporting purposes.

I was not suggesting that the acquiring companies "cook the books" to convince their shareholders that their CVR liabilities are smaller than the agreed upon terms of their agreements with the selling companies.

Instead, it's a simple accounting recognition that the chances that the entire CVR values will ever be paid out are very low. It means that the acquiring companies should not have the CVRs' entire face values used on their balance sheets. That would be an unrealistically higher liability for the acquiring company, and no company want their liabilities to be higher than need be.

It boils down to this. Most acquiiring companies do not pay out the entire negotiated value of their CVRs, as KayakerBC has always maintained.

jd

<< Previous
Bullboard Posts
Next >>